Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action

Till Sprenger, M Viana, C Tassorelli

Research output: Contribution to journalReview article

Abstract

A relatively high number of different medications is currently used for migraine prevention in clinical practice. Although these compounds were initially developed for other indications and differ in their mechanisms of action, some general themes can be identified from the mechanisms at play. Efficacious preventive drugs seem to either suppress excitatory nervous signaling via sodium and/or calcium receptors, facilitate GABAergic inhibition, reduce neuronal sensitization, block cortical spreading depression and/or reduce circulating levels of CGRP. We here review such mechanisms for the different compounds.

Original languageEnglish
Pages (from-to)313-323
Number of pages11
JournalNeurotherapeutics
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 2018

Fingerprint

Cortical Spreading Depression
Calcium-Sensing Receptors
Migraine Disorders
Action Potentials
Sodium
Pharmaceutical Preparations

Cite this

Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. / Sprenger, Till; Viana, M; Tassorelli, C.

In: Neurotherapeutics, Vol. 15, No. 2, 04.2018, p. 313-323.

Research output: Contribution to journalReview article

@article{4bd38d8f7bcc41c59c2ab60d1df092c7,
title = "Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action",
abstract = "A relatively high number of different medications is currently used for migraine prevention in clinical practice. Although these compounds were initially developed for other indications and differ in their mechanisms of action, some general themes can be identified from the mechanisms at play. Efficacious preventive drugs seem to either suppress excitatory nervous signaling via sodium and/or calcium receptors, facilitate GABAergic inhibition, reduce neuronal sensitization, block cortical spreading depression and/or reduce circulating levels of CGRP. We here review such mechanisms for the different compounds.",
author = "Till Sprenger and M Viana and C Tassorelli",
year = "2018",
month = "4",
doi = "10.1007/s13311-018-0621-8",
language = "English",
volume = "15",
pages = "313--323",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action

AU - Sprenger, Till

AU - Viana, M

AU - Tassorelli, C

PY - 2018/4

Y1 - 2018/4

N2 - A relatively high number of different medications is currently used for migraine prevention in clinical practice. Although these compounds were initially developed for other indications and differ in their mechanisms of action, some general themes can be identified from the mechanisms at play. Efficacious preventive drugs seem to either suppress excitatory nervous signaling via sodium and/or calcium receptors, facilitate GABAergic inhibition, reduce neuronal sensitization, block cortical spreading depression and/or reduce circulating levels of CGRP. We here review such mechanisms for the different compounds.

AB - A relatively high number of different medications is currently used for migraine prevention in clinical practice. Although these compounds were initially developed for other indications and differ in their mechanisms of action, some general themes can be identified from the mechanisms at play. Efficacious preventive drugs seem to either suppress excitatory nervous signaling via sodium and/or calcium receptors, facilitate GABAergic inhibition, reduce neuronal sensitization, block cortical spreading depression and/or reduce circulating levels of CGRP. We here review such mechanisms for the different compounds.

U2 - 10.1007/s13311-018-0621-8

DO - 10.1007/s13311-018-0621-8

M3 - Review article

C2 - 29671241

VL - 15

SP - 313

EP - 323

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 2

ER -